Belvedere Trading
AUPH icon

Belvedere Trading’s Aurinia Pharmaceuticals AUPH Stock Holding History

Belvedere Trading’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6,700
Closed -$33.6K – 692
2024
Q1 		$33.6K Sell
6,700
-3,900
-37% -$26.5K ﹤0.01% 541
2023
Q4 		$95.3K Buy
10,600
+5,900
+126% +$48.6K ﹤0.01% 469
2023
Q3 		$36.5K Buy
4,700
+2,500
+114% +$24.4K ﹤0.01% 453
2023
Q2 		$21.3K Sell
2,200
-300
-12% -$3.11K ﹤0.01% 654
2023
Q1 		$27.4K Hold
2,500
– – ﹤0.01% 670
2022
Q4 		$10.8K Buy
+2,500
New +$14.5K ﹤0.01% 899

Other funds holding AUPH

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Belvedere Trading's AUPH Position: Q2 2024 in Review

Belvedere Trading sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2024, closing a stake of 4,497 shares — an estimated $22.5K sold.

Belvedere Trading first reported a position in AUPH in Q4 2022 and held it in 5 quarters. The position peaked at $95.8K in Q1 2023. 171 funds tracked by Wall St. Rank hold AUPH as of Q2 2024.

  • Belvedere Trading reported no remaining Aurinia Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Belvedere Trading sold 4,497 Aurinia Pharmaceuticals shares in Q2 2024, an estimated $22.5K.
  • Belvedere Trading first reported a position in Aurinia Pharmaceuticals in Q4 2022 and held it in 5 quarters.
  • Belvedere Trading's Aurinia Pharmaceuticals position peaked at $95.8K in Q1 2023.
  • 171 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2024.

Based on Belvedere Trading's 13F filing for Q2 2024, filed 9 Aug 2024.